Zahner G, Schaper M, Panzer U, et al. Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation[J]. Biochem J, 2009, 422(3): 563-570.
[3]
Shui HA, Ka SM, Wu WM, et al. LPS-evoked IL-18 expression in mesangial cells plays a role in accelerating lupus nephritis[J]. Rheumatology, 2007, 46(8): 1277-1284.
[4]
Meyer-Schwesinger C, Dehde S, von Ruffer C, et al. Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappa B p65 signaling[J]. Am J Physiol Renal Physiol, 2009, 296(5): 1088-1099.
Sabry A, Elbasyouni SR, Sheashaa HA, et al. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian Patients with lupus nephritis[J].Int Urol Nephrol, 2006, 38(3-4): 731-737.
Chen H, Sun B, Pan S, et al. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo[J].Anticancer Drugs, 2009, 20(2): 131-140.
[15]
Noori S, Hassan ZM, Taghikhani M, et al. Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses[J].Int Immunopharmacol, 2010, 10(2): 213-217.
Natanson C, Hoffman WD, Suffredini AF, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis[J]. Ann Intern Med, 1994, 120(9): 771-783.
[20]
Noda T, Amano F. Differences in nitric oxide synthase activity in a macrophage-like cell line, RAW264.7 cells, treated with lipopolysaccharide (LPS) in the presence or absence of interferon-gamma (IFN-gamma): possible heterogeneity of iNOS activity[J]. J Biochem, 1997, 121(1): 38-46.
